• Kymera Therapeutics director Bruce Booth reported sales of 502,476 common shares on June 26-29 at weighted-average prices of $105.78-$118.66.
• Holdings attributed to Atlas Venture Fund X fell to 2,412,747 shares.
• Holdings attributed to Atlas Venture Opportunity Fund I fell to 466,077 shares.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kymera Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001451612-26-000018), on June 30, 2026, and is solely responsible for the information contained therein.